• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Eda Takeyoshi  江田 岳誉

ORCIDConnect your ORCID iD *help
… Alternative Names

EDA TAKEYOSHI  江田 岳誉

Less
Researcher Number 90772038
Other IDs
Affiliation (Current) 2025: 新潟大学, 医歯学総合病院, 薬剤師
Affiliation (based on the past Project Information) *help 2025: 新潟大学, 医歯学総合病院, 薬剤師
2017 – 2023: 新潟大学, 医歯学総合病院, 薬剤師
Review Section/Research Field
Principal Investigator
Basic Section 56010:Neurosurgery-related / Basic Section 47060:Clinical pharmacy-related / Pharmacology in pharmacy
Keywords
Principal Investigator
mTOR / metabolic reprogramming / glycolysis / HIF-1 / microenvironment / glioblastoma / タンパク合成 / 細胞内飢餓 / タンパク質合成 / AMPK … More / 膠芽腫 / がん代謝 / 薬理学 / 神経膠腫(グリオーマ) / グリオーマ / glioma / translational research / drug repositioning / xenograft / Glioblastoma Less
  • Research Projects

    (3 results)
  • Research Products

    (6 results)
  • Co-Researchers

    (3 People)
  •  患者由来BRAF遺伝子変異高度悪性神経膠腫細胞に対する放射線治療増感因子の探求Principal Investigator

    • Principal Investigator
      江田 岳誉
    • Project Period (FY)
      2025 – 2027
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Review Section
      Basic Section 56010:Neurosurgery-related
    • Research Institution
      Niigata University
  •  Establishment of drug therapy targeting metabolic reprogramming for glioblastomaPrincipal Investigator

    • Principal Investigator
      Eda Takeyoshi
    • Project Period (FY)
      2020 – 2023
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Review Section
      Basic Section 47060:Clinical pharmacy-related
    • Research Institution
      Niigata University
  •  Foundation of chemotherapy for malignant glioma targeting mTORPrincipal Investigator

    • Principal Investigator
      EDA TAKEYOSHI
    • Project Period (FY)
      2017 – 2020
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Research Field
      Pharmacology in pharmacy
    • Research Institution
      Niigata University

All 2023 2022 2019

All Journal Article Presentation

  • [Journal Article] Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide2022

    • Author(s)
      Eda T, Okada M, Ogura R, Tsukamoto Y, Kanemaru Y, Watanabe J, On J, Aoki H, Oishi M, Takei N, Fujii Y, Natsumeda M.
    • Journal Title

      Cancers (Basel)

      Volume: 14 Issue: 3 Pages: 770-770

    • DOI

      10.3390/cancers14030770

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-17K10888, KAKENHI-PROJECT-19K09476, KAKENHI-PROJECT-21H03042, KAKENHI-PROJECT-20K07194
  • [Journal Article] EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma2019

    • Author(s)
      Nozawa T , Okada M, Natsumeda M, Eda T, Abe H, Tsukamoto Y, Okamoto K, Oishi M, Takahashi H, Fujii Y, Kakita A
    • Journal Title

      Neurol. Med. Chir.(Tokyo)

      Volume: 59 Issue: 3 Pages: 89-97

    • DOI

      10.2176/nmc.oa.2018-0078

    • NAID

      130007612662

    • ISSN
      0470-8105, 1349-8029
    • Language
      English
    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K10888, KAKENHI-PROJECT-16H06276, KAKENHI-PROJECT-19K09476, KAKENHI-PROJECT-17K08304, KAKENHI-PROJECT-17K17739
  • [Presentation] Investigation of anti-tumor effects by inhibiting glucose uptake via sodium-glucose transporter 2 (SGLT2) expressed in glioblastoma cell lines2023

    • Author(s)
      江田岳誉、岡田正康、棗田学、大石誠、藤井幸彦、武井延之
    • Organizer
      第12回国際放射線神経生物学会大会
    • Data Source
      KAKENHI-PROJECT-20K07194
  • [Presentation] Investigation of anti-tumor effect by inhibiting glucose uptake via sodium-glucose transporter 2 (SGLT2) expressed in glioblastoma cell lines2023

    • Author(s)
      江田岳誉、岡田正康、棗田学、大石誠、藤井幸彦、武井延之
    • Organizer
      第12回国際放射線神経生物学会大会
    • Data Source
      KAKENHI-PROJECT-20K07194
  • [Presentation] Canagliflozin, a sodium-glucose transporter 2 (SGLT2) inhibitor, suppresses the growth of glioblastoma through the AMPK-mTOR signaling2022

    • Author(s)
      江田岳誉、棗田学、大石誠、藤井幸彦、武井延之
    • Organizer
      第96回日本薬理学会年会
    • Data Source
      KAKENHI-PROJECT-20K07194
  • [Presentation] mTORシグナルを標的とした悪性グリオーマに対する新規化学療法の基盤研究2019

    • Author(s)
      江田岳誉、金丸優、岡田正康、棗田学、大石誠、藤井幸彦
    • Organizer
      第92回日本薬理学会年会
    • Data Source
      KAKENHI-PROJECT-17K08304
  • 1.  棗田 学 (00515728)
    # of Collaborated Projects: 2 results
    # of Collaborated Products: 4 results
  • 2.  FUJII Yukihiko
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 3.  OISHI Makoto
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results

URL: 

Are you sure that you want to link your ORCID iD to your KAKEN Researcher profile?
* This action can be performed only by the researcher himself/herself who is listed on the KAKEN Researcher’s page. Are you sure that this KAKEN Researcher’s page is your page?

この研究者とORCID iDの連携を行いますか?
※ この処理は、研究者本人だけが実行できます。

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi